✦ LIBER ✦

P087 - SONIC: a randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy

✍ Scribed by J.F. Colombel; P. Rutgeerts; W. Reinisch; G.J. Mantzaris; A. Kornbluth; D. Rachmilewitz; S. Lichtiger; G. D'Haens; R.H. Diamond; D. Broussard; R. Hegedus; C.J. van der Woude; W.J. Sandborn

Book ID: 119636202
Publisher: Oxford University Press
Year: 2009
Tongue: English
Weight: 63 KB
Volume: 3
Category: Article
ISSN: 1873-9946
DOI: 10.1016/s1873-9946(09)60114-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

751f One Year Data from the Sonic Study:

751f One Year Data from the Sonic Study: A Randomized, Double-Blind Trial Comparing Infliximab and Infliximab Plus Azathioprine to Azathioprine in Patients with Crohn's Disease Naive to Immunomodulators and Biologic Therapy

✍ William J. Sandborn; Paul J. Rutgeerts; Walter Reinisch; Gerassimos J. Mantzaris 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 146 KB

143 Welcome: A Randomized, Double-Blind,

143 Welcome: A Randomized, Double-Blind, Controlled Trial Comparing Certolizumab Pegol 400 Mg Every 2 Weeks with Every 4 Weeks for Maintenance of Response and Remission in Patients with Moderate to Severe Crohn's Disease with Secondary Failure to Infliximab

✍ William J. Sandborn; Severine Vermeire; Geert R. D'Haens; Jean-Frederic Colombel 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 102 KB

13 - WELCOME: A randomized, double-blind

13 - WELCOME: A randomized, double-blind, controlled trial comparing certolizumab pegol 400mg every 2 weeks with every 4 weeks for maintenance of response and remission in patients with moderate-to-severe Crohn's disease with secondary failure to infliximab

✍ W.J. Sandborn; S. Vermeire; G. D'Haens; J.F. Colombel; R.N. Fedorak; M.E. Spehlm 📂 Article 📅 2009 🏛 Oxford University Press 🌐 English ⚖ 62 KB